Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%

Reuters

Feb 25

Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%

Overview

Cancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mln
Adjusted EBITDA for Q4-2025 reaches $0.95 mln, showing significant improvement
Company reports positive operating cash flow for Q4-2025, excluding unusual items

Outlook

Company to discuss 2026 prospects in shareholder call after 10K filing

Result Drivers

REVENUE GROWTH - Precipio's Q4-2025 revenue increased by 23% year-over-year to $6.7 mln
CASH FLOW POSITIVITY - Positive operating cash flow reported for Q4-2025, excluding unusual items

Company press release: ID:nGNX5kgQyj

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		$6.70 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614503566"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614503566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614503566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614503566","market":"us","top_or_hot":-1,"title":"Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23% </title></head><body><p><span>Overview</span></p><ul><li><p>Cancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mln</p></li><li><p>Adjusted EBITDA for Q4-2025 reaches $0.95 mln, showing significant improvement</p></li><li><p>Company reports positive operating cash flow for Q4-2025, excluding unusual items</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company to discuss 2026 prospects in shareholder call after 10K filing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Precipio's Q4-2025 revenue increased by 23% year-over-year to $6.7 mln</p></li><li><p>CASH FLOW POSITIVITY - Positive operating cash flow reported for Q4-2025, excluding unusual items</p></li></ul><p>Company press release: <span>ID:nGNX5kgQyj</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$6.70 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23% </title></head><body><p><span>Overview</span></p><ul><li><p>Cancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mln</p></li><li><p>Adjusted EBITDA for Q4-2025 reaches $0.95 mln, showing significant improvement</p></li><li><p>Company reports positive operating cash flow for Q4-2025, excluding unusual items</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company to discuss 2026 prospects in shareholder call after 10K filing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Precipio's Q4-2025 revenue increased by 23% year-over-year to $6.7 mln</p></li><li><p>CASH FLOW POSITIVITY - Positive operating cash flow reported for Q4-2025, excluding unusual items</p></li></ul><p>Company press release: <span>ID:nGNX5kgQyj</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$6.70 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL1N3ZL0Q8:1","article_id":"2614503566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614503566","pubTimestamp":1772030697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23%OverviewCancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mlnAdjusted EBITDA for Q4-2025 reaches $0.95 mln, s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","PRPO":"Precipio, Inc."},"translate_title":"血癌诊断公司Precipio第四季度prelim收入增长23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRPO":0.9},"content_text":"Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23% OverviewCancer diagnostics firm's preliminary Q4 revenue rises 23% yr/yr to $6.7 mlnAdjusted EBITDA for Q4-2025 reaches $0.95 mln, showing significant improvementCompany reports positive operating cash flow for Q4-2025, excluding unusual itemsOutlookCompany to discuss 2026 prospects in shareholder call after 10K filingResult DriversREVENUE GROWTH - Precipio's Q4-2025 revenue increased by 23% year-over-year to $6.7 mlnCASH FLOW POSITIVITY - Positive operating cash flow reported for Q4-2025, excluding unusual itemsCompany press release: ID:nGNX5kgQyjKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Revenue$6.70 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}